Is Levomilnacipran XR (Fetzima) in shortage in 2026? Get the latest update on availability, pricing, and what patients can do to find their medication.
If you're having trouble finding Levomilnacipran XR (brand name: Fetzima) at your pharmacy, you might assume there's a national shortage. The reality is more nuanced — and understanding the difference matters for how you handle the situation.
As of early 2026, Levomilnacipran XR is not listed on the FDA or ASHP drug shortage databases. That means manufacturers are producing the medication and distributing it to wholesalers. The drug isn't in shortage in the traditional sense.
But for patients who can't find it at their local pharmacy, that distinction doesn't make filling their prescription any easier. Let's unpack what's actually happening and what you can do about it.
The honest answer: Levomilnacipran XR has an availability problem, not a supply problem. Here's what that means:
Think of it like a book that's still in print but your local bookstore didn't order any copies. The book exists — it's just not where you need it to be.
Several factors contribute to the difficulty finding Levomilnacipran XR:
Levomilnacipran XR occupies a small slice of the antidepressant market. Most patients start treatment with more commonly prescribed medications like SSRIs or other SNRIs. Only a subset of patients — often those who haven't responded to first-line treatments — end up on Fetzima.
Many insurance plans place Levomilnacipran XR on higher formulary tiers (Tier 3 or 4) and require prior authorization or step therapy. This means fewer prescriptions are written, which further reduces pharmacy demand and stocking.
While generic levomilnacipran ER is FDA-approved, not all strengths are consistently available from generic manufacturers. Some pharmacies may carry one strength but not another, adding complexity to the fill process.
Brand-name Fetzima runs about $458 to $520 per month without insurance. Even generic versions can cost $150 to $400 per month. High-cost, low-demand medications are the first to be dropped from pharmacy inventory.
Here's a snapshot of current pricing:
For a full breakdown of savings options, read our guide to saving money on Levomilnacipran XR.
The antidepressant landscape continues to evolve. While Levomilnacipran XR remains the only SNRI with its particular norepinephrine-dominant profile, patients who can't access it have several established alternatives:
For details on each, see our alternatives guide.
Telehealth has also made it easier to get and maintain a Levomilnacipran XR prescription. Services like Thriveworks and other online psychiatry platforms can prescribe the medication and send it to any pharmacy — including mail-order options that may have better availability.
Here's a practical action plan:
For more detailed tips, read our guide on how to find Levomilnacipran XR in stock near you.
Levomilnacipran XR isn't in a traditional shortage in 2026 — but that's cold comfort if you can't find it at your pharmacy. The real issue is a combination of low demand, insurance barriers, inconsistent generic availability, and high cost that keeps this medication off many pharmacy shelves.
The good news is that the medication is available if you know where to look. Use the tools and strategies above, stay proactive about your refills, and talk to your doctor if access remains a persistent problem. Your depression treatment shouldn't depend on which pharmacy you happen to use.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
